Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Class A shares of the Alger Focus Equity Fund outperformed the Russell 1000 Growth Index during the fourth quarter of 2024.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index during the fourth quarter of 2024. Read ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Ongoing trials of the next generation of weight loss drugs are revealing something unexpected: Some patients are losing too ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...